{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T06:28:23Z","timestamp":1766557703937,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T00:00:00Z","timestamp":1597449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T00:00:00Z","timestamp":1597449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tsai family Fund and Boyd-Elsie Welin Professorship","award":["na"],"award-info":[{"award-number":["na"]}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University, Taiwan","doi-asserted-by":"crossref","award":["03G0000004A"],"award-info":[{"award-number":["03G0000004A"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Monoamine oxidase (MAO) A catalyzes oxidative deamination of monoamine neurotransmitters and dietary amines and regulates brain development and functions. Recently, we showed that MAO A mediates the progression and migration of glioma and MAO A inhibitors reduce glioma cell growth. Glioblastoma (GBM) is a common and most malignant brain tumor which is difficult to treat. Temozolomide (TMZ) is the current standard chemotherapy for glioma, but tumors usually become resistant and recur. So far, no effective therapy for TMZ-resistant glioma is available. Natural plant antimicrobial solution (PAMs) is a Chinese herbal medicine which has been used for decades without toxicity and has multiple medical functions including anti- inflammatory effects. Here, we report the effects of PAMs on glioblastoma growth.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The growth of TMZ -sensitive (U251S),-resistant (U251R) human glioma cells, and mouse glioma cell line GL-26 were assessed by MTS colorimetric assay, colony formation, and cell migration assays.<\/jats:p>\n<jats:p>Male C57BL\/6 mice were implanted subcutaneously or intracranial with luciferase-positive mouse glioma GL-26 cells and treated with vehicle; MAO A inhibitor clorgyline (10\u2009mg\/kg); TMZ (1\u2009mg\/kg); PAMs (48\u2009mg\/kg) alone or in combination with TMZ (1\u2009mg\/kg) for 14\u2009days. At the end of the treatment, mice were sacrificed, MAO A catalytic activity in tumors was measured, and tumor sizes were determined by imaging and weight.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>These results show that PAMs inhibits MAO A catalytic activity in all three glioma cell lines studied U251S, U251R, and GL-26. PAMs reduced glioma growth and has greater effects in combination with low dose of TMZ than PAMS or TMZ alone in all three cell lines as shown by MTS, colony formation, and cell migration assays. Using the subcutaneous or intracranial GL-26 glioma mouse model, PAMs reduced the tumor growth and MAO A activity, similar to the MAO A inhibitor clorgyline. Combining PAMs with non-toxic dose TMZ increased survival to a greater extent than those of PAMs or TMZ alone.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This is the first study which suggests that PAMs alone or co-administration with low doses of TMZ may be a potential adjuvant to reduce the toxicity of TMZ and to abrogate drug resistance for the effective treatment of glioma.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12906-020-03041-z","type":"journal-article","created":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T12:02:21Z","timestamp":1597492941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma"],"prefix":"10.1186","volume":"20","author":[{"given":"Pei-Chuan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danzhou","family":"Xiangfei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canquan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-His","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Chen","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,15]]},"reference":[{"issue":"7","key":"3041_CR1","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1172\/JCI70982","volume":"124","author":"JB Wu","year":"2014","unstructured":"Wu JB, Shao C, Li X, Li Q, Hu P, Shi C, Li Y, Chen YT, Yin F, Liao CP, et al. Monoamine oxidase a mediates prostate tumorigenesis and cancer metastasis. J Clin Invest. 2014;124(7):2891\u2013908.","journal-title":"J Clin Invest"},{"issue":"12","key":"3041_CR2","doi-asserted-by":"publisher","first-page":"13842","DOI":"10.18632\/oncotarget.7283","volume":"7","author":"S Kushal","year":"2016","unstructured":"Kushal S, Wang W, Vaikari VP, Kota R, Chen K, Yeh TS, Jhaveri N, Groshen SL, Olenyuk BZ, Chen TC, et al. Monoamine oxidase A (MAO A) inhibitors decrease glioma progression. Oncotarget. 2016;7(12):13842\u201353.","journal-title":"Oncotarget"},{"issue":"2","key":"3041_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/path.4944","volume":"243","author":"PC Li","year":"2017","unstructured":"Li PC, Siddiqi IN, Mottok A, Loo EY, Wu CH, Cozen W, Steidl C, Shih JC. Monoamine oxidase a is highly expressed in classical Hodgkin lymphoma. J Pathol. 2017;243(2):220\u20139.","journal-title":"J Pathol"},{"issue":"13","key":"3041_CR4","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1073\/pnas.85.13.4934","volume":"85","author":"AW Bach","year":"1988","unstructured":"Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC. cDNA cloning of human liver monoamine oxidase a and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci U S A. 1988;85(13):4934\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"3041_CR5","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1111\/j.1471-4159.1989.tb09223.x","volume":"52","author":"NC Lan","year":"1989","unstructured":"Lan NC, Chen CH, Shih JC. Expression of functional human monoamine oxidase a and B cDNAs in mammalian cells. J Neurochem. 1989;52(5):1652\u20134.","journal-title":"J Neurochem"},{"issue":"4","key":"3041_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrn1883","volume":"7","author":"MB Youdim","year":"2006","unstructured":"Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7(4):295\u2013309.","journal-title":"Nat Rev Neurosci"},{"issue":"11","key":"3041_CR7","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm.2537","volume":"17","author":"SM Weis","year":"2011","unstructured":"Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17(11):1359\u201370.","journal-title":"Nat Med"},{"issue":"5 Suppl","key":"3041_CR8","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1188\/16.CJON.S1.2-8","volume":"20","author":"ME Davis","year":"2016","unstructured":"Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20(5 Suppl):S2\u20138.","journal-title":"Clin J Oncol Nurs"},{"issue":"10","key":"3041_CR9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"key":"3041_CR10","first-page":"3485","volume":"9","author":"F Han","year":"2016","unstructured":"Han F, Hu R, Yang H, Liu J, Sui J, Xiang X, Wang F, Chu L, Song S. PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis. OncoTargets and therapy. 2016;9:3485\u201392.","journal-title":"OncoTargets and therapy"},{"issue":"6","key":"3041_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrc823","volume":"2","author":"BP Sorrentino","year":"2002","unstructured":"Sorrentino BP. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat Rev Cancer. 2002;2(6):431\u201341.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3041_CR12","doi-asserted-by":"publisher","first-page":"e0176823","DOI":"10.1371\/journal.pone.0176823","volume":"12","author":"R Dou","year":"2017","unstructured":"Dou R, Liu Z, Yuan X, Xiangfei D, Bai R, Bi Z, Yang P, Yang Y, Dong Y, Su W, et al. PAMs ameliorates the imiquimod-induced psoriasis-like skin disease in mice by inhibition of translocation of NF-kappaB and production of inflammatory cytokines. PLoS One. 2017;12(5):e0176823.","journal-title":"PLoS One"},{"issue":"4","key":"3041_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1556\/2060.105.2018.4.30","volume":"105","author":"M Eslami-Farsani","year":"2018","unstructured":"Eslami-Farsani M, Moslehi A, Hatami-Shahmir A. Allantoin improves histopathological evaluations in a rat model of gastritis. Physiol Int. 2018;105(4):325\u201334.","journal-title":"Physiol Int"},{"issue":"12","key":"3041_CR14","doi-asserted-by":"publisher","first-page":"BR482","DOI":"10.12659\/MSM.883592","volume":"18","author":"I Hodorova","year":"2012","unstructured":"Hodorova I, Rybarova S, Vecanova J, Solar P, Domorakova I, Adamkov M, Mihalik J. Comparison of expression pattern of monoamine oxidase a with histopathologic subtypes and tumour grade of renal cell carcinoma. Med Sci Monit. 2012;18(12):BR482\u20136.","journal-title":"Med Sci Monit"},{"issue":"2","key":"3041_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.canlet.2011.08.015","volume":"312","author":"N Jhaveri","year":"2011","unstructured":"Jhaveri N, Cho H, Torres S, Wang W, Schonthal AH, Petasis NA, Louie SG, Hofman FM, Chen TC. Noscapine inhibits tumor growth in TMZ-resistant gliomas. Cancer Lett. 2011;312(2):245\u201352.","journal-title":"Cancer Lett"},{"issue":"6","key":"3041_CR16","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1021\/ja512613j","volume":"137","author":"JB Wu","year":"2015","unstructured":"Wu JB, Lin TP, Gallagher JD, Kushal S, Chung LW, Zhau HE, Olenyuk BZ, Shih JC. Monoamine oxidase a inhibitor-near-infrared dye conjugate reduces prostate tumor growth. J Am Chem Soc. 2015;137(6):2366\u201374.","journal-title":"J Am Chem Soc"},{"issue":"2","key":"3041_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/cancers2020693","volume":"2","author":"A Conti","year":"2010","unstructured":"Conti A, Guli C, La Torre D, Tomasello C, Angileri FF, Aguennouz M. Role of inflammation and oxidative stress mediators in gliomas. Cancers. 2010;2(2):693\u2013712.","journal-title":"Cancers"},{"key":"3041_CR18","doi-asserted-by":"publisher","first-page":"149185","DOI":"10.1155\/2014\/149185","volume":"2014","author":"G Landskron","year":"2014","unstructured":"Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.","journal-title":"J Immunol Res"},{"issue":"1","key":"3041_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57\u201370.","journal-title":"Cell"},{"issue":"13","key":"3041_CR20","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1016\/S0142-9612(02)00013-3","volume":"23","author":"JS Gill","year":"2002","unstructured":"Gill JS, Zhu X, Moore MJ, Lu L, Yaszemski MJ, Windebank AJ. Effects of NFkappaB decoy oligonucleotides released from biodegradable polymer microparticles on a glioblastoma cell line. Biomaterials. 2002;23(13):2773\u201381.","journal-title":"Biomaterials"},{"issue":"5","key":"3041_CR21","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3171\/jns.2002.96.5.0909","volume":"96","author":"S Nagai","year":"2002","unstructured":"Nagai S, Washiyama K, Kurimoto M, Takaku A, Endo S, Kumanishi T. Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg. 2002;96(5):909\u201317.","journal-title":"J Neurosurg"},{"issue":"4","key":"3041_CR22","first-page":"50","volume":"31","author":"F Zhen","year":"2015","unstructured":"Zhen F, Song M, Liu Z, Zhou Y, Li D, Mao CQ. Antimicrobial effects and mechanisms of natural plant antimicrobial solution against Staphylococcus aureus. J Biol. 2015;31(4):50\u20134.","journal-title":"J Biol"},{"issue":"4","key":"3041_CR23","first-page":"26","volume":"36","author":"X Yuan","year":"2019","unstructured":"Yuan X, Qiu JY, Wang SY, Dou R, Xiangfei D, Yang P, Mao CQ. Inhibitory effects and preliminary molecular mechanisms of \u201cnatural plant antimicrobial solution\u201d (PAMs) on liver cancer HepG2 cells. J Biol. 2019;36(4):26\u20139.","journal-title":"J Biol"},{"issue":"6","key":"3041_CR24","first-page":"712","volume":"46","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Dou R, Bi Z, Yang Y, Liu Z, Wu Y, Qiu J, Wu C, Xiangfei D, Li D, Mao CQ. Promotion of apoptosis in leukemia K562 cells by natural plant antimicrobial solution (PAMs). J China Pharmaceutical Univ. 2015;46(6):712\u20138.","journal-title":"J China Pharmaceutical Univ"},{"issue":"5","key":"3041_CR25","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.cellsig.2006.12.012","volume":"19","author":"L Lessard","year":"2007","unstructured":"Lessard L, Saad F, Le Page C, Diallo JS, Peant B, Delvoye N, Mes-Masson AM. NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells. Cellular signaling. 2007;19(5):1093\u2013100.","journal-title":"Cellular signaling"},{"issue":"6","key":"3041_CR26","first-page":"2010","volume":"27","author":"F Chen","year":"2012","unstructured":"Chen F, Yang D, Che X, Wang J, Li X, Zhang Z, Chen X, Song X. Livin mediates tumor cell invasion in the DU-145 cell line via NF-kappaB. Oncol Rep. 2012;27(6):2010\u20136.","journal-title":"Oncol Rep"},{"issue":"1","key":"3041_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12943-017-0688-6","volume":"16","author":"D Ren","year":"2017","unstructured":"Ren D, Yang Q, Dai Y, Guo W, Du H, Song L, Peng X. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-kappaB signaling pathway. Mol Cancer. 2017;16(1):117.","journal-title":"Mol Cancer"},{"issue":"6","key":"3041_CR28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s10495-017-1368-0","volume":"22","author":"J Zhang","year":"2017","unstructured":"Zhang J, Kuang Y, Wang Y, Xu Q, Ren Q. Notch-4 silencing inhibits prostate cancer growth and EMT via the NF-kappaB pathway. Apoptosis. 2017;22(6):877\u201384.","journal-title":"Apoptosis"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-020-03041-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-020-03041-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-020-03041-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T23:05:41Z","timestamp":1628982341000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-020-03041-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,15]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3041"],"URL":"https:\/\/doi.org\/10.1186\/s12906-020-03041-z","relation":{},"ISSN":["2662-7671"],"issn-type":[{"type":"electronic","value":"2662-7671"}],"subject":[],"published":{"date-parts":[[2020,8,15]]},"assertion":[{"value":"21 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The experimental protocol was established, according to the ethical guidelines and was approved by the Institutional Animal Care and Use Committee (IACUC) of University of Southern California (IACUC protocol number 20212). The detail of mice euthanasia methods is following the IACCU guideline, anesthesia with CO2 or isoflurane (1\u20133% inhalant to effect) will be used for euthanasia of mice. Isoflurane is the standard inhalant anesthetic, delivered to effect in concentrations of 1\u20133% in oxygen (up to 5% for initial induction), using a precision vaporizer. After surgery, the anesthetic monitoring of mice includes testing of rear foot reflexes before any incision is made, and continual observation of respiratory pattern, mucous membrane color, and responsiveness to manipulations and rear foot reflexes throughout the procedure. This research is not an application for clinical research, an institutional review board (IRB) is not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"252"}}